title: Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
abstract: A group of 69 men with bladder outflow obstruction due to benign prostatic hyperplasia (BPH) were treated in a double-blind placebo-controlled study with finasteride (Proscar), a 5 alpha-reductase inhibitor, 5 mg or 10 mg/day, or an identical placebo for 3 months; subsequently, 20 patients received finasteride 5 mg/day in an open extension study. Ten of these patients have now completed 3 years of therapy and have been reevaluated with pressure/flow urodynamics. In finasteride-treated patients dihydrotestosterone (DHT) declined by over 60%, remaining unchanged with placebo. Symptom scores fell in both groups of patients, maximum flow rate values decreased on placebo but improved by a mean of 1.5 ml/s in the 10-mg group and 3.3 ml/s in the 5-mg group. After 1 year of therapy, the reduction in symptom score was well maintained and the flow rate had increased by a mean of 2.7 ml/s; the mean prostate volume was reduced by 14% and prostate-specific antigen (PSA) had declined by 28%. In the 10 patients treated for 3 years who consented to further urodynamic study, the maximum urinary flow rate had improved from a mean baseline value of 8.7 ml/s to a mean of 13.8 ml/s, while maximum subtracted voiding pressure had decreased from a mean baseline value of 72 cm H2O to an unobstructed mean value of 44 cm H2O. Side effects were minimal and reversible on stopping the medication.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Urology and Diagnostic Radiology, St. Bartholomew's Hospital, London, UK.
authors.forename: R S
authors.initials: RS
authors.lastname: Kirby
authors.forename: J
authors.initials: J
authors.lastname: Vale
authors.forename: J
authors.initials: J
authors.lastname: Bryan
authors.forename: K
authors.initials: K
authors.lastname: Holmes
authors.forename: J A
authors.initials: JA
authors.lastname: Webb
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000368:Aged; D000369:Aged, 80 and over; D000736:Androstenes / Q000494:pharmacology / Q000627:therapeutic use*; D001378:Azasteroids / Q000494:pharmacology / Q000627:therapeutic use*; D013196:Dihydrotestosterone / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D018120:Finasteride; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood / Q000187:drug effects; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D058891:5-alpha Reductase Inhibitors; D000736:Androstenes; D001378:Azasteroids; D013196:Dihydrotestosterone; D018120:Finasteride; D017430:Prostate-Specific Antigen